A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation

Rationale and Protocol Design for the WJOG8515L Study

Hidetoshi Hayashi, Yasutaka Chiba, Kazuko Sakai, Tomonobu Fujita, Hiroshige Yoshioka, Daisuke Sakai, Chiyoe Kitagawa, Tateaki Naito, Koji Takeda, Isamu Okamoto, Tetsuya Mitsudomi, Yutaka Kawakami, Kazuto Nishio, Shinichiro Nakamura, Nobuyuki Yamamoto, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Antibodies to programmed cell death–1 (PD-1), such as nivolumab, have shown promising clinical activity in patients with advanced non–small-cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation–positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are patients who are T790M-positive. The WJOG8515L study (UMIN ID: 000021133) is a randomized phase II trial to compare nivolumab with the combination of carboplatin and pemetrexed in patients with EGFR mutation–positive nonsquamous NSCLC who have developed resistance to EGFR-TKIs due to mechanisms other than T790M. Eligible patients are those with stage IV or recurrent EGFR mutation–positive NSCLC who experience disease progression after therapy with more than 1 EGFR-TKI, including gefitinib, erlotinib, or afatinib; they must show no evidence of the T790M mutation on analysis of a tumor biopsy specimen obtained after progression on such EGFR-TKI therapy, or, if T790M is detected, they must again experience progression on subsequent treatment with a third-generation EGFR-TKI. The primary endpoint is progression-free survival (PFS), and secondary end points include overall survival (OS), objective response rate, duration of response, safety, and OS and PFS according to PD-L1 expression level. Recruitment started in May 2016 and is ongoing.

Original languageEnglish
Pages (from-to)719-723
Number of pages5
JournalClinical Lung Cancer
Volume18
Issue number6
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Pemetrexed
erbB-1 Genes
Carboplatin
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Disease-Free Survival
nivolumab
Survival
Therapeutics
Disease Progression
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation : Rationale and Protocol Design for the WJOG8515L Study. / Hayashi, Hidetoshi; Chiba, Yasutaka; Sakai, Kazuko; Fujita, Tomonobu; Yoshioka, Hiroshige; Sakai, Daisuke; Kitagawa, Chiyoe; Naito, Tateaki; Takeda, Koji; Okamoto, Isamu; Mitsudomi, Tetsuya; Kawakami, Yutaka; Nishio, Kazuto; Nakamura, Shinichiro; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko.

In: Clinical Lung Cancer, Vol. 18, No. 6, 01.11.2017, p. 719-723.

Research output: Contribution to journalArticle

Hayashi, Hidetoshi ; Chiba, Yasutaka ; Sakai, Kazuko ; Fujita, Tomonobu ; Yoshioka, Hiroshige ; Sakai, Daisuke ; Kitagawa, Chiyoe ; Naito, Tateaki ; Takeda, Koji ; Okamoto, Isamu ; Mitsudomi, Tetsuya ; Kawakami, Yutaka ; Nishio, Kazuto ; Nakamura, Shinichiro ; Yamamoto, Nobuyuki ; Nakagawa, Kazuhiko. / A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation : Rationale and Protocol Design for the WJOG8515L Study. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 6. pp. 719-723.
@article{b90f93bf53534f9aa7be5c6bda1467ed,
title = "A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study",
abstract = "Antibodies to programmed cell death–1 (PD-1), such as nivolumab, have shown promising clinical activity in patients with advanced non–small-cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation–positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are patients who are T790M-positive. The WJOG8515L study (UMIN ID: 000021133) is a randomized phase II trial to compare nivolumab with the combination of carboplatin and pemetrexed in patients with EGFR mutation–positive nonsquamous NSCLC who have developed resistance to EGFR-TKIs due to mechanisms other than T790M. Eligible patients are those with stage IV or recurrent EGFR mutation–positive NSCLC who experience disease progression after therapy with more than 1 EGFR-TKI, including gefitinib, erlotinib, or afatinib; they must show no evidence of the T790M mutation on analysis of a tumor biopsy specimen obtained after progression on such EGFR-TKI therapy, or, if T790M is detected, they must again experience progression on subsequent treatment with a third-generation EGFR-TKI. The primary endpoint is progression-free survival (PFS), and secondary end points include overall survival (OS), objective response rate, duration of response, safety, and OS and PFS according to PD-L1 expression level. Recruitment started in May 2016 and is ongoing.",
author = "Hidetoshi Hayashi and Yasutaka Chiba and Kazuko Sakai and Tomonobu Fujita and Hiroshige Yoshioka and Daisuke Sakai and Chiyoe Kitagawa and Tateaki Naito and Koji Takeda and Isamu Okamoto and Tetsuya Mitsudomi and Yutaka Kawakami and Kazuto Nishio and Shinichiro Nakamura and Nobuyuki Yamamoto and Kazuhiko Nakagawa",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.cllc.2017.05.012",
language = "English",
volume = "18",
pages = "719--723",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation

T2 - Rationale and Protocol Design for the WJOG8515L Study

AU - Hayashi, Hidetoshi

AU - Chiba, Yasutaka

AU - Sakai, Kazuko

AU - Fujita, Tomonobu

AU - Yoshioka, Hiroshige

AU - Sakai, Daisuke

AU - Kitagawa, Chiyoe

AU - Naito, Tateaki

AU - Takeda, Koji

AU - Okamoto, Isamu

AU - Mitsudomi, Tetsuya

AU - Kawakami, Yutaka

AU - Nishio, Kazuto

AU - Nakamura, Shinichiro

AU - Yamamoto, Nobuyuki

AU - Nakagawa, Kazuhiko

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Antibodies to programmed cell death–1 (PD-1), such as nivolumab, have shown promising clinical activity in patients with advanced non–small-cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation–positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are patients who are T790M-positive. The WJOG8515L study (UMIN ID: 000021133) is a randomized phase II trial to compare nivolumab with the combination of carboplatin and pemetrexed in patients with EGFR mutation–positive nonsquamous NSCLC who have developed resistance to EGFR-TKIs due to mechanisms other than T790M. Eligible patients are those with stage IV or recurrent EGFR mutation–positive NSCLC who experience disease progression after therapy with more than 1 EGFR-TKI, including gefitinib, erlotinib, or afatinib; they must show no evidence of the T790M mutation on analysis of a tumor biopsy specimen obtained after progression on such EGFR-TKI therapy, or, if T790M is detected, they must again experience progression on subsequent treatment with a third-generation EGFR-TKI. The primary endpoint is progression-free survival (PFS), and secondary end points include overall survival (OS), objective response rate, duration of response, safety, and OS and PFS according to PD-L1 expression level. Recruitment started in May 2016 and is ongoing.

AB - Antibodies to programmed cell death–1 (PD-1), such as nivolumab, have shown promising clinical activity in patients with advanced non–small-cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation–positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are patients who are T790M-positive. The WJOG8515L study (UMIN ID: 000021133) is a randomized phase II trial to compare nivolumab with the combination of carboplatin and pemetrexed in patients with EGFR mutation–positive nonsquamous NSCLC who have developed resistance to EGFR-TKIs due to mechanisms other than T790M. Eligible patients are those with stage IV or recurrent EGFR mutation–positive NSCLC who experience disease progression after therapy with more than 1 EGFR-TKI, including gefitinib, erlotinib, or afatinib; they must show no evidence of the T790M mutation on analysis of a tumor biopsy specimen obtained after progression on such EGFR-TKI therapy, or, if T790M is detected, they must again experience progression on subsequent treatment with a third-generation EGFR-TKI. The primary endpoint is progression-free survival (PFS), and secondary end points include overall survival (OS), objective response rate, duration of response, safety, and OS and PFS according to PD-L1 expression level. Recruitment started in May 2016 and is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=85020687518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020687518&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2017.05.012

DO - 10.1016/j.cllc.2017.05.012

M3 - Article

VL - 18

SP - 719

EP - 723

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -